Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

(Not actual size)*

*Actual size is 14.4 mm x 5.3 mm.

SAPS-PD:

Measuring the efficacy of NUPLAZID in the pivotal trial

Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

(Not actual size)*

*Actual size is 14.4 mm x 5.3 mm.

SAPS-PD is a 9-item scale derived from SAPS that evaluates hallucinations and delusions in patients with
PD psychosis1

Types of Hallucinations Measured1 Types of Delusions Measured1
  • Auditory
  • Voices conversing
  • Somatic or tactile
  • Visual
  • Global rating of severity
  • Persecutory
  • Jealousy
  • Reference
  • Global rating of severity
Example SAPS Item: Global Hallucinations2
Scale Severity Patient Response
0 None  
1 Questionable  
2 Mild Hallucinations definitely present, but occur infrequently: at times the patient may question their existance
3 Moderate Hallucinations are vivid and occur occasionally; they may bother the patient to some extent
4 Marked Hallucinations are quite vivid, occur frequently, and pervade the patient's life
5 Severe Hallucinations occur almost daily and are sometimes unusual or bizarre; they are very vivid and extremely troubling

Each item is scored on a scale of 0 (none) to 5 (severe), for a maximum score of 45.3

This is a representation of one item of the full SAPS scale.

A 2.33-point change in the SAPS-PD is associated with clinically meaningful improvement — equivalent to a 1-point change in CGI-I1

 
Important Safety Information for NUPLAZID (pimavanserin)
  • Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

 
For healthcare professionals